All In Biotech

Drug Trial Radar · NCT04786964

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

25

Actual

Start

Dec 8, 2021

Primary completion

Dec 30, 2023

Study completion Dec 30, 2023

Sponsor

Lead sponsor
Checkpoint Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an efficacy and safety study of cosibelimab (CK-301) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease. Participants will be randomly assigned in a 2:1 ratio to receive cosibelimab combined with pemetrexed/platinum (Investigators choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators choice of cisplatin or carboplatin). The primary hypothesis is that cosibelimab in combination with pemetrexed/platinum chemotherapy prolongs Overall Survival (OS) compared to pemetrexed/platinum chemotherapy alone.

Conditions

  • Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

  • CosibelimabDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • PemetrexedDrug

    IV infusion

  • Folic acid 350-1000 μgDietary supplement

    Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

  • Vitamin B12 1000 μgDietary supplement

    Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

  • Dexamethasone 4mgDrug

    For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Approximately 3 years.

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Vitória, Brazil

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Kota Bharu, Malaysia

  • Research Site

    Wellington, New Zealand

  • Research Site

    Lima, Peru

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Kaliningrad, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Kursk, Russia

  • Research Site

    Kuzmolovskiy, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Samara, Russia

  • Research Site

    Sochi, Russia

  • Research Site

    Tomsk, Russia

  • Research Site

    Volgograd, Russia

  • Research Site

    Pretoria, South Africa

  • Research Site

    Chiang Mai, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.